Christian R. Florey-Schultze

Carl Neuberg Str. 1
Hannover, NI 30625, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

γδ T cells show distinct responses to CMV after stem cell transplantation.

γδ T cells show distinct responses to CMV after stem cell transplantation.

Journal: Journal of molecular medicine (Berlin, Germany)

Published: April 10, 2026

Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.

Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.

Journal: Journal of hematology & oncology

Published: April 06, 2026

Real-world experience with Tabelecleucel within and beyond the approval label.

Real-world experience with Tabelecleucel within and beyond the approval label.

Journal: Blood advances

Published: December 02, 2025

Real-world experience with tabelecleucel within and beyond the approval label.

Real-world experience with tabelecleucel within and beyond the approval label.

Journal: Blood advances

Published: December 02, 2025

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis.

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis.

Journal: Blood cancer journal

Published: November 08, 2025

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Haematologica

Published: October 17, 2025

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Haematologica

Published: October 17, 2025

The Berlin-Hannover ICANS severity assessment-a novel bedside test to evaluate CAR T-cell-associated neurotoxicity.

The Berlin-Hannover ICANS severity assessment-a novel bedside test to evaluate CAR T-cell-associated neurotoxicity.

Journal: Frontiers in neurology

Published: October 16, 2025

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.

Journal: Blood advances

Published: September 15, 2025

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.

Journal: Blood advances

Published: September 15, 2025

Point-of-Care Anti-CD19-CAR T-cell Therapy Induces Renal Remission in Refractory Myeloperoxidase-Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.

Point-of-Care Anti-CD19-CAR T-cell Therapy Induces Renal Remission in Refractory Myeloperoxidase-Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.

Journal: Kidney international reports

Published: April 16, 2025

Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis.

Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis.

Journal: HemaSphere

Published: January 30, 2025

Showing 1-12 of 42

Last Updated: 09/26/2026